Eric J. Small, MD, of the University of California, San Francisco, discusses phase III findings on apalutamide vs placebo in patients with nonmetastatic castration-resistant prostate cancer (Abstract 161).
John J. Coen, MD, of 21st Century Oncology, discusses phase II study findings on selective bladder preservation with twice-daily radiation plus fluorouracil/cisplatin or daily radi...
Daniel J. George, MD, of Duke University Medical Center, discusses study findings on cabozantinib vs sunitinib for previously untreated patients with advanced renal cell carcinoma ...
Robert G. Bristow, MD, PhD, of Manchester Cancer Research Centre, discusses germline and somatic mutations; new ways to generate biomarkers that may describe tumor complexity; and ...
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he chaired on prostate cancer, which included discussion of daily vs weekly image-guided radiotherapy;...
Joaquim Bellmunt, MD, PhD, of the Dana-Farber Cancer Institute, discusses phase III 2-year follow-up findings on pembrolizumab vs investigator’s choice (paclitaxel, docetaxel, or v...